Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advantages in cannabinoid research.

R Mechoulam1

  • 1Hebrew University, Medical Faculty, Jerusalem, Israel. Mechou@yam-suff.cc.huji.ac.il

Forschende Komplementarmedizin
|November 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the molecular basis of cannabidiolic acid methyl Ester's anti-depressive effects in a rat model of treatment-resistant depression.

Journal of psychiatric research·2024
Same author

Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression.

Behavioural brain research·2018
Same author

Cannabis and epilepsy.

Epilepsy & behavior : E&B·2017
Same author

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Current oncology (Toronto, Ont.)·2016
Same author

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.

Cell death & disease·2012
Same author

The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex.

British journal of pharmacology·2012
Same journal

Independent replication of pre-clinical research in homeopathy: a systematic review.

Forschende Komplementarmedizin·2000
Same journal

[Evaluation and critical review published in the European literature on osteopathic studies in the clinical field and in the area of fundamental research].

Forschende Komplementarmedizin·2000
Same journal

Simple chemiluminescence assays for free radicals in venous blood and serum samples: results in atopic, psoriasis, MCS and cancer patients.

Forschende Komplementarmedizin·2000
Same journal

Cannabis in movement disorders.

Forschende Komplementarmedizin·2000
Same journal

[Cannabis and cannabinoids in medicine].

Forschende Komplementarmedizin·2000
Same journal

[New curriculum for earning the certification for phytotherapy SGMP (Swiss Medical Society for Phytotherapy)].

Forschende Komplementarmedizin·2000
See all related articles

Delta-9-THC, the active cannabis component, acts via CB1 and CB2 receptors, mimicking natural cannabinoids. Research explores its therapeutic potential for various conditions, including neurological disorders.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Cannabinoid Research

Background:

  • The active component of cannabis, Delta-9-Tetrahydrocannabinol (Delta9-THC), was isolated decades ago, but its mechanism of action was unclear until recently.
  • Significant advancements in the last decade have identified specific cannabinoid receptors (CB1 and CB2) as the targets for Delta9-THC.
  • Endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), share physiological activities mimicked by Delta9-THC.

Purpose of the Study:

  • To elucidate the mechanism of action of Delta9-THC.
  • To review the established and potential therapeutic applications of Delta9-THC and synthetic cannabinoids.
  • To highlight ongoing research into novel cannabinoid-based treatments.

Main Methods:

  • Review of established scientific literature on Delta9-THC and cannabinoid receptors.

Related Experiment Videos

  • Analysis of clinical data regarding the efficacy of cannabinoids in treating various medical conditions.
  • Examination of preclinical and clinical trial data for synthetic cannabinoids like HU-211.

    • Main Results:

    • Delta9-THC exerts its effects by interacting with CB1 and CB2 receptors.
    • Cannabinoids mimic the actions of endogenous compounds like anandamide and 2-AG.
    • Delta9-THC is approved for chemotherapy-induced nausea and appetite stimulation in AIDS patients.
    • Investigational use of cannabinoids includes managing multiple sclerosis symptoms, pain, and neurological conditions.

    Conclusions:

    • The understanding of Delta9-THC's mode of action has significantly advanced through receptor identification.
    • Cannabinoids demonstrate therapeutic value in both approved and potential applications, particularly in managing symptoms and diseases.
    • Synthetic cannabinoids like HU-211 show promise for treating neurological damage, including traumatic brain injury and stroke.